Suven Pharma Sets $1 Billion Revenue Target by 2030 with CDMO Expansion

is setting ambitious goals, aiming to reach $1 billion in revenue by 2030, fueled by its expansion in the Contract Development and Manufacturing Organization (CDMO) business. The company is strengthening its position in the global pharmaceutical sector by focusing on high-margin opportunities and expanding its capabilities in drug development and manufacturing. With increasing demand for CDMO services, Suven Pharma is scaling up its operations to cater to both emerging biotech firms and established pharmaceutical giants. The company is investing in R&D, capacity expansion, and strategic partnerships to drive long-term growth. As the CDMO industry gains momentum, Suven Pharma’s roadmap includes enhancing its global presence and tapping into innovative drug solutions. The company's focus on quality, compliance, and efficiency makes it a key player in the evolving pharmaceutical manufacturing landscape. Source: NDTV Profit No Recommendations